AMPK: An emerging target for modification of injury-induced pain plasticity

Neuroscience Letters

Volumn 557, Issue , 2013, Pages 9-18

  Price, Theodore J ^a   Dussor, Gregory ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

AMPK; Chronic pain; ERK; MTOR; Plasticity; Sodium channels

Indexed keywords

6,7 DIHYDRO 4 HYDROXY 3 (2' HYDROXY 1,1' BIPHENYL 4 YL) 6 OXOTHIENO[2,3 B]PYRIDINE 5 CARBONITRILE; ADENYLATE KINASE; CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR2.1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENFORMIN; RESVERATROL; SALICYLIC ACID; SODIUM CHANNEL NAV1.7; UBIQUITIN PROTEIN LIGASE NEDD4;

CELL METABOLISM; CHRONIC PAIN; ENZYME PHOSPHORYLATION; GENE EXPRESSION; LONG TERM POTENTIATION; NERVE CELL EXCITABILITY; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROPATHIC PAIN; PERIPHERAL NERVE INJURY; POSTOPERATIVE PAIN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; REVIEW; SENSORY NERVE CELL;

AMPK; CHRONIC PAIN; ERK; MTOR; PLASTICITY; SODIUM CHANNELS;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; HUMANS; MICE; NEURALGIA; NEURONAL PLASTICITY; PAIN; PERIPHERAL NERVE INJURIES; PHOSPHORYLATION; RATS; SIGNAL TRANSDUCTION;

EID: 84890154557     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.06.060     Document Type: Review

References (113)

1. Institute of Medicine Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research, Washington (DC) 2011.
2. Aasvang E.K., Hansen J.B., Kehlet H. Late sensory function after intraoperative capsaicin wound instillation. Acta Anaesthesiol. Scand. 2010, 54:224-231.
3. Aasvang E.K., Hansen J.B., Malmstrom J., Asmussen T., Gennevois D., Struys M.M., Kehlet H. The effect of wound instillation of a novel purified capsaicin formulation on postherniotomy pain: a double-blind, randomized, placebo-controlled study. Anesth. Analg. 2008, 107:282-291.
4. Adams J.P., Anderson A.E., Varga A.W., Dineley K.T., Cook R.G., Pfaffinger P.J., Sweatt J.D. The A-type potassium channel Kv4.2 is a substrate for the mitogen-activated protein kinase ERK. J. Neurochem. 2000, 75:2277-2287.
5. Andersen M.N., Rasmussen H.B. AMPK. A regulator of ion channels. Commun. Integr. Biol. 2012, 5:480-484.
6. Argetsinger L.S., Hsu G.W., Myers M.G., Billestrup N., White M.F., Carter-Su C. Growth hormone, interferon-gamma, and leukemia inhibitory factor promoted tyrosyl phosphorylation of insulin receptor substrate-1. J. Biol. Chem. 1995, 270:14685-14692.
7. Asante C.O., Wallace V.C., Dickenson A.H. Mammalian target of rapamycin signaling in the spinal cord is required for neuronal plasticity and behavioral hypersensitivity associated with neuropathy in the rat. J. Pain 2010.
8. Asiedu M.N., Tillu D.V., Melemedjian O.K., Shy A., Sanoja R., Bodell B., Ghosh S., Porreca F., Price T.J. Spinal protein kinase M {zeta} underlies the maintenance mechanism of persistent nociceptive sensitization. J. Neurosci. 2011, 31:6646-6653.
9. Banik R.K., Subieta A.R., Wu C., Brennan T.J. Increased nerve growth factor after rat plantar incision contributes to guarding behavior and heat hyperalgesia. Pain 2005, 117:68-76.
10. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., Prabhu V.V., Allard J.S., Lopez-Lluch G., Lewis K., Pistell P.J., Poosala S., Becker K.G., Boss O., Gwinn D., Wang M., Ramaswamy S., Fishbein K.W., Spencer R.G., Lakatta E.G., Le Couteur D., Shaw R.J., Navas P., Puigserver P., Ingram D.K., de Cabo R., Sinclair D.A. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
11. Bazzo K.O., Souto A.A., Lopes T.G., Zanin R.F., Gomez M.V., Souza A.H., Campos M.M. Evidence for the analgesic activity of resveratrol in acute models of nociception in mice. J. Nat. Prod. 2013, 76:13-21.
12. Benhamou D., Berti M., Brodner G., De Andres J., Draisci G., Moreno-Azcoita M., Neugebauer E.A., Schwenk W., Torres L.M., Viel E. Postoperative Analgesic THerapy Observational Survey (PATHOS): a practice pattern study in 7 central/southern European countries. Pain 2008, 136:134-141.
13. Bhalla V., Oyster N.M., Fitch A.C., Wijngaarden M.A., Neumann D., Schlattner U., Pearce D., Hallows K.R. AMP-activated kinase inhibits the epithelial Na+ channel through functional regulation of the ubiquitin ligase Nedd4-2. J. Biol. Chem. 2006, 281:26159-26169.
14. Blanco Martinez de Morentin P., Gonzalez C.R., Saha A.K., Martins L., Dieguez C., Vidal-Puig A., Tena-Sempere M., Lopez M. Hypothalamic AMP-activated protein kinase as a mediator of whole body energy balance. Rev. Endocr. Metab. Disord. 2011, 12:127-140.
15. Bogen O., Alessandri-Haber N., Chu C., Gear R.W., Levine J.D. Generation of a pain memory in the primary afferent nociceptor triggered by PKCepsilon activation of CPEB. J. Neurosci.: Off. J. Soc. Neurosci. 2012, 32:2018-2026.
16. Bongiorno D., Schuetz F., Poronnik P., Adams D.J. Regulation of voltage-gated ion channels in excitable cells by the ubiquitin ligases Nedd4 and Nedd4-2. Channels (Austin) 2011, 5:79-88.
17. Brennan T.J. Postoperative models of nociception. Ilar. J. 1999, 40:129-136.
18. Brennan T.J., Vandermeulen E.P., Gebhart G.F. Characterization of a rat model of incisional pain. Pain 1996, 64:493-501.
19. Carattino M.D., Edinger R.S., Grieser H.J., Wise R., Neumann D., Schlattner U., Johnson J.P., Kleyman T.R., Hallows K.R. Epithelial sodium channel inhibition by AMP-activated protein kinase in oocytes and polarized renal epithelial cells. J. Biol. Chem. 2005, 280:17608-17616.
20. Carling D., Thornton C., Woods A., Sanders M.J. AMP-activated protein kinase: new regulation, new roles?. Biochem. J. 2012, 445:11-27.
21. Carracedo A., Ma L., Teruya-Feldstein J., Rojo F., Salmena L., Alimonti A., Egia A., Sasaki A.T., Thomas G., Kozma S.C., Papa A., Nardella C., Cantley L.C., Baselga J., Pandolfi P.P. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 2008, 118:3065-3074.
22. Chan A.Y., Dolinsky V.W., Soltys C.L., Viollet B., Baksh S., Light P.E., Dyck J.R. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J. Biol. Chem. 2008, 283:24194-24201.
23. Clark J.D., Shi X., Li X., Qiao Y., Liang D., Angst M.S., Yeomans D.C. Morphine reduces local cytokine expression and neutrophil infiltration after incision. Mol. Pain 2007, 3:28.
24. Cool B., Zinker B., Chiou W., Kifle L., Cao N., Perham M., Dickinson R., Adler A., Gagne G., Iyengar R., Zhao G., Marsh K., Kym P., Jung P., Camp H.S., Frevert E. Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome. Cell Metab. 2006, 3:403-416.
25. Corradetti M.N., Inoki K., Bardeesy N., DePinho R.A., Guan K.L. Regulation of the TSC pathway by LKB1: evidence of a molecular link between tuberous sclerosis complex and Peutz-Jeghers syndrome. Genes Dev. 2004, 18:1533-1538.
26. Crombie I.K., Davies H.T., Macrae W.A. Cut and thrust: antecedent surgery and trauma among patients attending a chronic pain clinic. Pain 1998, 76:167-171.
27. Dasgupta B., Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:7217-7222.
28. Dib-Hajj S.D., Cummins T.R., Black J.A., Waxman S.G. Sodium channels in normal and pathological pain. Annu. Rev. Neurosci. 2010, 33:325-347.
29. Dieguez C., Vazquez M.J., Romero A., Lopez M., Nogueiras R. Hypothalamic control of lipid metabolism: focus on leptin, ghrelin and melanocortins. Neuroendocrinology 2011, 94:1-11.
30. Duncan A.I., Koch C.G., Xu M., Manlapaz M., Batdorf B., Pitas G., Starr N. Recent metformin ingestion does not increase in-hospital morbidity or mortality after cardiac surgery. Anesth. Analg. 2007, 104:42-50.
31. Egan D.F., Shackelford D.B., Mihaylova M.M., Gelino S., Kohnz R.A., Mair W., Vasquez D.S., Joshi A., Gwinn D.M., Taylor R., Asara J.M., Fitzpatrick J., Dillin A., Viollet B., Kundu M., Hansen M., Shaw R.J. Phosphorylation of ULK1 (hATG1) by AMP-activated protein kinase connects energy sensing to mitophagy. Science 2011, 331:456-461.
32. Eijkelkamp N., Wang H., Garza-Carbajal A., Willemen H.L., Zwartkruis F.J., Wood J.N., Dantzer R., Kelley K.W., Heijnen C.J., Kavelaars A. Low nociceptor GRK2 prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to Epac/Rap1, protein kinase Cepsilon, and MEK/ERK. J. Neurosci.: Off. J. Soc. Neurosci. 2010, 30:12806-12815.
33. Estacion M., Waxman S.G., Dib-Hajj S.D. Effects of ranolazine on wild-type and mutant hNav1.7 channels and on DRG neuron excitability. Mol. Pain 2010, 6:35.
34. Ferrari L.F., Bogen O., Chu C., Levine J.D. Peripheral administration of translation inhibitors reverses increased hyperalgesia in a model of chronic pain in the rat. J. Pain 2013.
35. Foller M., Jaumann M., Dettling J., Saxena A., Pakladok T., Munoz C., Ruth P., Sopjani M., Seebohm G., Ruttiger L., Knipper M., Lang F. AMP-activated protein kinase in BK-channel regulation and protection against hearing loss following acoustic overstimulation. FASEB J.: Off. Publ. Feder. Am. Soc. Exp. Biol. 2012, 26:4243-4253.
36. Fullerton M.D., Steinberg G.R. SIRT1 takes a backseat to AMPK in the regulation of insulin sensitivity by resveratrol. Diabetes 2010, 59:551-553.
37. Gentilli M., Mazoit J.X., Bouaziz H., Fletcher D., Casper R.F., Benhamou D., Savouret J.F. Resveratrol decreases hyperalgesia induced by carrageenan in the rat hind paw. Life Sci. 2001, 68:1317-1321.
38. Geranton S.M., Jimenez-Diaz L., Torsney C., Tochiki K.K., Stuart S.A., Leith J.L., Lumb B.M., Hunt S.P. A rapamycin-sensitive signaling pathway is essential for the full expression of persistent pain states. J. Neurosci. 2009, 29:15017-15027.
39. Ghosh S., Tergaonkar V., Rothlin C.V., Correa R.G., Bottero V., Bist P., Verma I.M., Hunter T. Essential role of tuberous sclerosis genes TSC1 and TSC2 in NF-kappaB activation and cell survival. Cancer Cell 2006, 10:215-226.
40. Giordanetto F., Karis D. Direct AMP-activated protein kinase activators: a review of evidence from the patent literature. Expert Opin. Ther. Pat. 2012, 22:1467-1477.
41. Gowardman J.R., Havill J. Fatal metformin induced lactic acidosis: case report. N. Z. Med. J. 1995, 108:230-231.
42. Hallows K.R., Raghuram V., Kemp B.E., Witters L.A., Foskett J.K. Inhibition of cystic fibrosis transmembrane conductance regulator by novel interaction with the metabolic sensor AMP-activated protein kinase. J. Clin. Invest. 2000, 105:1711-1721.
43. Hanley M.A., Jensen M.P., Smith D.G., Ehde D.M., Edwards W.T., Robinson L.R. Preamputation pain and acute pain predict chronic pain after lower extremity amputation. J. Pain 2007, 8:102-109.
44. Hawley S.A., Fullerton M.D., Ross F.A., Schertzer J.D., Chevtzoff C., Walker K.J., Peggie M.W., Zibrova D., Green K.A., Mustard K.J., Kemp B.E., Sakamoto K., Steinberg G.R., Hardie D.G. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 2012, 336:918-922.
45. Hoyt S.B., London C., Gorin D., Wyvratt M.J., Fisher M.H., Abbadie C., Felix J.P., Garcia M.L., Li X., Lyons K.A., McGowan E., MacIntyre D.E., Martin W.J., Priest B.T., Ritter A., Smith M.M., Warren V.A., Williams B.S., Kaczorowski G.J., Parsons W.H. Discovery of a novel class of benzazepinone Na(v)1.7 blockers: potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 2007, 17:4630-4634.
46. Hoyt S.B., London C., Ok H., Gonzalez E., Duffy J.L., Abbadie C., Dean B., Felix J.P., Garcia M.L., Jochnowitz N., Karanam B.V., Li X., Lyons K.A., McGowan E., Macintyre D.E., Martin W.J., Priest B.T., Smith M.M., Tschirret-Guth R., Warren V.A., Williams B.S., Kaczorowski G.J., Parsons W.H. Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain. Bioorg. Med. Chem. Lett. 2007, 17:6172-6177.
47. Ikematsu N., Dallas M.L., Ross F.A., Lewis R.W., Rafferty J.N., David J.A., Suman R., Peers C., Hardie D.G., Evans A.M. Phosphorylation of the voltage-gated potassium channel Kv2.1 by AMP-activated protein kinase regulates membrane excitability. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:18132-18137.
48. Jakobsen S.N., Hardie D.G., Morrice N., Tornqvist H.E. 5'-AMP-activated protein kinase phosphorylates IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide riboside. J. Biol. Chem. 2001, 276:46912-46916.
49. Ji R.R., Gereau R.W.T., Malcangio M., Strichartz G.R. MAP kinase and pain. Brain Res. Rev. 2009, 60:135-148.
50. Jimenez-Diaz L., Geranton S.M., Passmore G.M., Leith J.L., Fisher A.S., Berliocchi L., Sivasubramaniam A.K., Sheasby A., Lumb B.M., Hunt S.P. Local translation in primary afferent fibers regulates nociception. PLoS One 2008, 3:e1961.
51. Johansen A., Romundstad L., Nielsen C.S., Schirmer H., Stubhaug A. Persistent postsurgical pain in a general population: prevalence and predictors in the Tromso study. Pain 2012, 153:1390-1396.
52. Kehlet H., Jensen T.S., Woolf C.J. Persistent postsurgical pain: risk factors and prevention. Lancet 2006, 367:1618-1625.
53. Kelleher 3rd R.J., Govindarajan A., Tonegawa S. Translational regulatory mechanisms in persistent forms of synaptic plasticity. Neuron 2004, 44:59-73.
54. Kim J., Yoon M.Y., Choi S.L., Kang I., Kim S.S., Kim Y.S., Choi Y.K., Ha J. Effects of stimulation of AMP-activated protein kinase on insulin-like growth factor 1- and epidermal growth factor-dependent extracellular signal-regulated kinase pathway. J. Biol. Chem. 2001, 276:19102-19110.
55. King J.D., Fitch A.C., Lee J.K., McCane J.E., Mak D.O., Foskett J.K., Hallows K.R. AMP-activated protein kinase phosphorylation of the R domain inhibits PKA stimulation of CFTR. Am. J. Physiol. Cell Physiol. 2009, 297:C94-C101.
56. King R.B. Topical aspirin in chloroform and the relief of pain due to herpes zoster and postherpetic neuralgia. Arch. Neurol. 1993, 50:1046-1053.
57. Laboureyras E., Chateauraynaud J., Richebe P., Simonnet G. Long-term pain vulnerability after surgery in rats: prevention by nefopam, an analgesic with antihyperalgesic properties. Anesth. Analg. 2009, 109:623-631.
58. Labuzek K., Liber S., Marcol W., Okopien B. Controlling newly diagnosed type 2 diabetes mellitus with metformin managed pain symptoms in a patient affected with Dercum's disease. Pain Med. 2012, 13:1526-1527.
59. Labuzek K., Liber S., Suchy D., Okopien B. A successful case of pain management using metformin in a patient with adiposis dolorosa. Int. J. Clin. Pharmacol. Ther. 2013.
60. Lee K.H., Hsu E.C., Guh J.H., Yang H.C., Wang D., Kulp S.K., Shapiro C.L., Chen C.S. Targeting energy metabolic and oncogenic signaling pathways in triple-negative breast cancer by a novel adenosine monophosphate-activated protein kinase (AMPK) activator. J. Biol. Chem. 2011, 286:39247-39258.
61. Li F.Q., Fowler K.A., Neil J.E., Colton C.A., Vitek M.P. An apolipoprotein E-mimetic stimulates axonal regeneration and remyelination after peripheral nerve injury. J. Pharmacol. Exp. Ther. 2010, 334:106-115.
62. Liang L., Tao B., Fan L., Yaster M., Zhang Y., Tao Y.X. mTOR and its downstream pathway are activated in the dorsal root ganglion and spinal cord after peripheral inflammation, but not after nerve injury. Brain Res. 2013, 1513:17-25.
63. London C., Hoyt S.B., Parsons W.H., Williams B.S., Warren V.A., Tschirret-Guth R., Smith M.M., Priest B.T., McGowan E., Martin W.J., Lyons K.A., Li X., Karanam B.V., Jochnowitz N., Garcia M.L., Felix J.P., Dean B., Abbadie C., Kaczorowski G.J., Duffy J.L. Imidazopyridines: a novel class of hNav1.7 channel blockers. Bioorg. Med. Chem. Lett. 2008, 18:1696-1701.
64. Lopez M., Varela L., Vazquez M.J., Rodriguez-Cuenca S., Gonzalez C.R., Velagapudi V.R., Morgan D.A., Schoenmakers E., Agassandian K., Lage R., Martinez de Morentin P.B., Tovar S., Nogueiras R., Carling D., Lelliott C., Gallego R., Oresic M., Chatterjee K., Saha A.K., Rahmouni K., Dieguez C., Vidal-Puig A. Hypothalamic AMPK and fatty acid metabolism mediate thyroid regulation of energy balance. Nat. Med. 2010, 16:1001-1008.
65. Ma W., Quirion R. The ERK/MAPK pathway, as a target for the treatment of neuropathic pain. Expert Opin. Ther. Targets 2005, 9:699-713.
66. Malik-Hall M., Dina O.A., Levine J.D. Primary afferent nociceptor mechanisms mediating NGF-induced mechanical hyperalgesia. Eur. J. Neurosci. 2005, 21:3387-3394.
67. Martin S.W., Butcher A.J., Berrow N.S., Richards M.W., Paddon R.E., Turner D.J., Dolphin A.C., Sihra T.S., Fitzgerald E.M. Phosphorylation sites on calcium channel alpha1 and beta subunits regulate ERK-dependent modulation of neuronal N-type calcium channels. Cell Calcium 2006, 39:275-292.
68. Matthews P., Derry S., Moore R.A., McQuay H.J. Topical rubefacients for acute and chronic pain in adults. Cochr. Database Syst. Rev. 2009, CD007403.
69. Melemedjian O., Asiedu M.N., Tillu D.V., Sanoja R., Yan J., Lark A., Khoutorsky A., Johnson J., Peebles K.A., Lepow T., Sonenberg N., Dussor G.O., Price T.J. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol. Pain 2011, 21(7):70. 10.1186/1744-8069-7-70.
70. Melemedjian O.K., Asiedu M.N., Tillu D.V., Peebles K.A., Yan J., Ertz N., Dussor G.O., Price T.J. Price, IL-6- and NGF-induced rapid control of protein synthesis and nociceptive plasticity via convergent signaling to the eIF4F complex. J. Neurosci. 2010, 30:15113-15123.
71. Melemedjian O.K., Asiedu M.N., Tillu D.V., Sanoja R., Yan J., Lark A., Khoutorsky A., Johnson J., Peebles K.A., Lepow T., Sonenberg N., Dussor G., Price T.J. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol. Pain 2011, 7:70.
72. Melemedjian O.K., Khoutorsky A., Sorge R.E., Yan J., Asiedu M.N., Valdez A., Ghosh S., Dussor G., Mogil J.S., Sonenberg N., Price T.J. mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. Pain 2013, 154(7):1080-1091. 10.1016/j.pain.2013.03.021.
73. Melemedjian O.K., Yassine H.N., Shy A., Price T.J. Proteomic and functional annotation analysis of injured peripheral nerves reveals ApoE as a protein upregulated by injury that is modulated by metformin treatment. Mol. Pain 2013, 9:14.
74. Nassar M.A., Levato A., Stirling L.C., Wood J.N. Neuropathic pain develops normally in mice lacking both Na(v)1.7 and Na(v)1.8. Mol. Pain 2005, 1:24.
75. Nassar M.A., Stirling L.C., Forlani G., Baker M.D., Matthews E.A., Dickenson A.H., Wood J.N. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:12706-12711.
76. Norsted Gregory E., Codeluppi S., Gregory J.A., Steinauer J., Svensson C.I. Mammalian target of rapamycin in spinal cord neurons mediates hypersensitivity induced by peripheral inflammation. Neuroscience 2010, 169:1392-1402.
77. Obara I., Geranton S.M., Hunt S.P. Axonal protein synthesis: a potential target for pain relief?. Curr. Opin. Pharmacol. 2012, 12:42-48.
78. Obata K., Yamanaka H., Dai Y., Mizushima T., Fukuoka T., Tokunaga A., Noguchi K. Differential activation of MAPK in injured and uninjured DRG neurons following chronic constriction injury of the sciatic nerve in rats. Eur. J. Neurosci. 2004, 20:2881-2895.
79. Ouyang J., Parakhia R.A., Ochs R.S. Metformin activates AMP kinase through inhibition of AMP deaminase. J. Biol. Chem. 2011, 286:1-11.
80. Owen M.R., Doran E., Halestrap A.P. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 2000, 348(Pt 3):607-614.
81. Pasinetti G.M., Wang J., Marambaud P., Ferruzzi M., Gregor P., Knable L.A., Ho L. Neuroprotective and metabolic effects of resveratrol: Therapeutic implications for Huntington's disease and other neurodegenerative disorders. Exp. Neurol. 2011, 232(1):1-6. 10.1016/j.expneurol.2011.08.014.
82. Perkins F.M., Kehlet H. Chronic pain as an outcome of surgery. A review of predictive factors. Anesthesiology 2000, 93:1123-1133.
83. Pham-Marcou T.A., Beloeil H., Sun X., Gentili M., Yaici D., Benoit G., Benhamou D., Mazoit J.X. Antinociceptive effect of resveratrol in carrageenan-evoked hyperalgesia in rats: prolonged effect related to COX-2 expression impairment. Pain 2008, 140:274-283.
84. Lu J., Pop-Busui R., Lopes N., Jones T.L., BARI 2D Investigators Prevalence of diabetic peripheral neuropathy and relation to glycemic control therapies at baseline in the BARI 2D cohort. Peripher. Nerv. Syst. 2009, 14:1-13.
85. Potter W.B., O'Riordan K.J., Barnett D., Osting S.M., Wagoner M., Burger C., Roopra A. Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One 2010, 5:e8996.
86. Price T.J., Geranton S.M. Translating nociceptor sensitivity: the role of axonal protein synthesis in nociceptor physiology. Eur. J. Neurosci. 2009, 29:2253-2263.
87. Price T.J., Rashid M.H., Millecamps M., Sanoja R., Entrena J.M., Cervero F. Decreased nociceptive sensitization in mice lacking the fragile X mental retardation protein: role of mGluR1/5 and mTOR. J. Neurosci. 2007, 27:13958-13967.
88. Roy Chowdhury S.K., Smith D.R., Saleh A., Schapansky J., Marquez A., Gomes S., Akude E., Morrow D., Calcutt N.A., Fernyhough P. Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 2012, 135:1751-1766.
89. Schmalhofer W.A., Calhoun J., Burrows R., Bailey T., Kohler M.G., Weinglass A.B., Kaczorowski G.J., Garcia M.L., Koltzenburg M., Priest B.T. ProTx-II, a selective inhibitor of NaV1.7 sodium channels, blocks action potential propagation in nociceptors. Mol. Pharmacol. 2008, 74:1476-1484.
90. Schrader L.A., Birnbaum S.G., Nadin B.M., Ren Y., Bui D., Anderson A.E., Sweatt J.D. ERK/MAPK regulates the Kv4.2 potassium channel by direct phosphorylation of the pore-forming subunit. Am. J. Physiol. Cell Physiol. 2006, 290:C852-C861.
91. Schug S.A. Persistent post-surgical pain: a view from the other side of the fence. Pain 2012, 153:1344-1345.
92. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., Montminy M., Cantley L.C. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
93. Shih M.H., Kao S.C., Wang W., Yaster M., Tao Y.X. Spinal cord NMDA receptor-mediated activation of mammalian target of rapamycin is required for the development and maintenance of bone cancer-induced pain hypersensitivities in rats. J. Pain 2012, 13:338-349.
94. Sirvinskas E., Kinduris S., Kapturauskas J., Samalavicius R. Perioperative use of metformin in cardiac surgery. Medicina (Kaunas) 2010, 46:723-729.
95. Sonenberg N., Hinnebusch A.G. Regulation of translation initiation in eukaryotes: mechanisms and biological targets. Cell 2009, 136:731-745.
96. Spasic M.R., Callaerts P., Norga K.K. AMP-activated protein kinase (AMPK) molecular crossroad for metabolic control and survival of neurons. The Neuroscientist: A Review Journal Bringing Neurobiology Neurology and Psychiatry 2009, 15:309-316.
97. Stamboulian S., Choi J.S., Ahn H.S., Chang Y.W., Tyrrell L., Black J.A., Waxman S.G., Dib-Hajj S.D. ERK1/2 mitogen-activated protein kinase phosphorylates sodium channel Na(v)1.7 and alters its gating properties. J. Neurosci. 2010, 30:1637-1647.
98. Sukhodub A., Jovanovic S., Du Q., Budas G., Clelland A.K., Shen M., Sakamoto K., Tian R., Jovanovic A. AMP-activated protein kinase mediates preconditioning in cardiomyocytes by regulating activity and trafficking of sarcolemmal ATP-sensitive K(+) channels. J. Cell. Physiol. 2007, 210:224-236.
99. Tillu D.V., Melemedjian O.K., Asiedu M.N., Qu N., De Felice M., Dussor G., Price T.J. Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Mol. Pain 2012, 8:5.
100. Tyagarajan S., Chakravarty P.K., Zhou B., Taylor B., Fisher M.H., Wyvratt M.J., Lyons K., Klatt T., Li X., Kumar S., Williams B., Felix J., Priest B.T., Brochu R.M., Warren V., Smith M., Garcia M., Kaczorowski G.J., Martin W.J., Abbadie C., McGowan E., Jochnowitz N., Parsons W.H. Substituted biaryl pyrazoles as sodium channel blockers. Bioorg. Med. Chem. Lett. 2010, 20:5480-5483.
101. Tzatsos A., Tsichlis P.N. Energy depletion inhibits phosphatidylinositol 3-kinase/Akt signaling and induces apoptosis via AMP-activated protein kinase-dependent phosphorylation of IRS-1 at Ser-794. J. Biol. Chem. 2007, 282:18069-18082.
102. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., Janle E.M., Lobo J., Ferruzzi M.G., Davies P., Marambaud P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 2010, 285:9100-9113.
103. Vreven R., De Kock M. Metformin lactic acidosis and anaesthesia: myth or reality?. Acta Anaesthesiol. Belg. 2005, 56:297-302.
104. Wu C., Boustany L., Liang H., Brennan T.J. Nerve growth factor expression after plantar incision in the rat. Anesthesiology 2007, 107:128-135.
105. Wu C., Erickson M.A., Xu J., Wild K.D., Brennan T.J. Expression profile of nerve growth factor after muscle incision in the rat. Anesthesiology 2009, 110:140-149.
106. Wuertz K., Quero L., Sekiguchi M., Klawitter M., Nerlich A., Konno S., Kikuchi S., Boos N. The red wine polyphenol resveratrol shows promising potential for the treatment of nucleus pulposus-mediated pain in vitro and in vivo. Spine (Phila Pa 1976) 2011, 36:E1373-E1384.
107. Yan J., Melemedjian O.K., Price T.J., Dussor G. Sensitization of dural afferents underlies migraine-related behavior following meningeal application of interleukin-6 (IL-6). Mol. Pain 2012, 8:6.
108. Yoshida H., Bao L., Kefaloyianni E., Taskin E., Okorie U., Hong M., Dhar-Chowdhury P., Kaneko M., Coetzee W.A. AMP-activated protein kinase connects cellular energy metabolism to KATP channel function. J. Mol. Cell Cardiol. 2012, 52:410-418.
109. Zahn P.K., Subieta A., Park S.S., Brennan T.J. Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J. Pain: Off. J. Am. Pain Soc. 2004, 5:157-163.
110. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., Wierzbicki M., Verbeuren T.J., Cohen R.A. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
111. Zhou G., Myers R., Li Y., Chen Y., Shen X., Fenyk-Melody J., Wu M., Ventre J., Doebber T., Fujii N., Musi N., Hirshman M.F., Goodyear L.J., Moller D.E. Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 2001, 108:1167-1174.
112. Zhuang Z.Y., Xu H., Clapham D.E., Ji R.R. Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J. Neurosci.: Off. J. Soc. Neurosci. 2004, 24:8300-8309.
113. Zoncu R., Efeyan A., Sabatini D.M. mTOR: from growth signal integration to cancer, diabetes and ageing. Nat. Rev. Mol. Cell Biol. 2011, 12:21-35.